RESULTS

Human mAbs to DENV inhibit ZIKV infection
Previous studies have established that the EDE1-C8 and EDE1-C10 mAbs bind to and neutralize ZIKV with half-maximal effective concentration (EC 50 ) values ranging from 9 to 14 ng/ml 10, 30 . We compared the ability of another EDE1 mAb, EDE1-B10, to neutralize the four serotypes of DENV and the two lineages of ZIKV. EDE1-B10 strongly neutralized virions of the DENV-1, DENV-2, and DENV-3 serotypes (EC 50 ~28-138 ng/ml) and showed weaker activity against virions of the more distantly related DENV-4 serotype (Fig. 1a) . We tested EDE1-B10 for its ability to inhibit virus strains that represented the African (HD78788) and Asian-American (Brazil PE243) lineages of ZIKV and found that it had a stronger neutralization profile (EC 50 ~2-4 ng/ml) than that of EDE1-C8 and other published EDE-specific mAbs 10, 16 (Fig. 1b) . As with other EDE-specific mAbs, EDE1-B10 engages a quaternary epitope on the virion and does not bind monomeric E protein although the epitope is restored on covalently linked E-dimers 30, 31 . Like many other flavivirus-specific antibodies, subneutralizing concentrations of EDE-specific mAbs can trigger ADE of FcγR-expressing myeloid cells. To prevent possible ADE, we engineered LALA substitutions into the Fc region of EDE1-B10 and EDE1-C8, which disrupted engagement of the mAbs with Fc receptors and prevented ADE, but did not change neutralizing activity against ZIKV (Fig. 1c,d) 32 . Thus, mAbs to DENV EDE strongly neutralize ZIKV infection, and LALA variants that do not promote ADE can be generated without a loss of inhibitory activity in cell culture.
EDE1 mAb therapy controls ZIKV infection
We tested EDE-specific human mAbs for their ability to protect mice against ZIKV-induced lethality when administered as a postexposure therapy. To create a lethal challenge model in 4-to 5 weekold C57BL/6 mice, we passively transferred a blocking antibody specific for the type I interferon receptor Ifnar1 1 d before infection with 10 3 focus-forming units (FFUs) of a mouse-adapted African strain of ZIKV (ZIKV-Dakar) 18, 19 . The mice were then treated with a single dose of EDE1-B10, EDE1-C8 (EC 50 = 2-15 ng/ml), EDE2-A11 (EC 50 = 69-125 ng/ml) 10 , or an isotype control mAb (Flu 28C) 1 d (day +1; 100 µg), 3 d (day +3; 250 µg), or 5 d (day +5; 250 µg) after infection and the weight and survival of the mice were monitored for 21 d ( Fig. 2a and Figure 1 EDE1-B10 is a human mAb to DENV that cross-neutralizes ZIKV infection. (a) Serial dilutions of EDE1-B10 were tested for neutralization of DENV-1, DENV-2, DENV-3, and DENV-4 serotypes using a focus-reduction neutralization test. (b) EDE1-B10 was tested for neutralization of ZIKV strains from Africa (HD78788) and Brazil (PE243). The data in a,b are expressed as the percentage of neutralized virus. (c,d) ADE (c) and neutralization (d) studies with WT and LALA recombinant variants of EDE1-B10 and EDE1-C8 with DENV-2 (16681) and ZIKV (HD78788). Infection of U937 cells (c) in the presence of mAbs EDE1-B10, EDE1-C8, or their LALA mutants is presented as the percentage of infection. Data are representative of three independent experiments (a-d). Supplementary Fig. 1 ). The mice that were administered EDE1-B10, EDE1-C8, or EDE2-A11 were protected against lethality when they were treated at 1 or 3 d after infection. Furthermore, treatment with EDE1-B10 at 5 d after infection resulted in partial protection against lethality and weight loss ( Fig. 2a and Supplementary Fig. 1 ). Given the greater neutralization activity of EDE1-B10 in vitro, relative to that with the other EDE-specific mAbs, and its ability to robustly protect against lethality, most of the subsequent in vivo studies were performed with only EDE1-B10.
As a first step toward determining how EDE1 mAbs protect against disease, we defined the kinetics of viral dissemination for the tissues of interest. Within 2 d of infection, ZIKV RNA was readily detectable in the serum (1.7 × 10 5 FFU equivalents per ml; Fig. 2b ), brain (3.5 × 10 3 FFU equivalents per g tissue; Fig. 2c ), testis (4.8 × 10 3 FFU equivalents per g tissue; Fig. 2d ), epididymis (5.0 × 10 2 FFU equivalents per g tissue; Fig. 2e ), and eye (8.8 × 10 2 FFU equivalents per g tissue; Fig. 2f ). At the last time point assessed (day +5), viral titers were still increasing in these organs. (a) Four-to five-week-old male WT mice were treated with anti-Ifnar1 followed by s.c. infection with mouse-adapted ZIKV-Dakar. Mice were then treated with isotype control mAb or EDE1-B10 at day +1 (100 µg, left), day +3 (250 µg, middle), or day +5 (250 µg, right) after infection. Weight and survival data were pooled from two (EDE1-B10) or three (isotype) independent experiments (isotype-mAb-treated, n = 19 mice per group; EDE1-B10-treated, n = 10 mice per group). (b-f) Eight-to nine-week-old male WT mice were treated with anti-Ifnar1 followed by s.c. inoculation with mouse-adapted ZIKV-Dakar. Viral RNA was measured in serum (b), brain (c), testis (d), epididymis (e), and eye (f) by qRT-PCR at 1 d (D+1), 3 d (D+3), or 5 d (D+5) after infection. Bars indicate median values from two experimental replicates (n = 8 mice per group). (g-k) Eight-to nine-week-old male WT mice were treated with anti-Ifnar1 followed by subcutaneous inoculation with mouse-adapted ZIKV-Dakar. Mice were treated with isotype control mAb or EDE1-B10 at day +1 (100 µg) or day +3 (250 µg) after infection. At day +5 after infection, viral RNA was measured in serum (g), brain (h), testis (i), epididymis (j), and eye (k). Bars indicate median values collected from two experimental replicates (n = 8 mice per group). (l-o) Eight-to nine-week-old male WT mice were treated with anti-Ifnar1 followed by s.c. inoculation with mouse-adapted ZIKV-Dakar. Mice were treated with isotype control mAb or EDE1-B10 at day +1 (100 µg; isotype, n = 9; EDE1-B10, n = 10), day +3 (250 µg; isotype, n = 10; EDE1-B10, n = 15), or day +5 (250 µg; isotype, n = 8; EDE1-B10, n = 9) after infection. At day +21 after infection, viral RNA was measured in the brain (l), testis (m), epididymis (n), and eye (o). Bars indicate median values collected from three experimental replicates. Throughout, the dashed lines indicate the limit of detection of the assay. *P < 0.05, **P < 0.001, and ***P < 0.0001 (logrank (a) or Mann-Whitney (g-n) test). Data from two (a, b-k) or three (a, l-o) independent experiments (a: mean ± s.d.).
A r t i c l e s
We then evaluated the efficacy of EDE1-B10 therapy on the control of ZIKV infection at different immune-privileged sites during the acute and persistent phases of infection. Adult C57BL/6 male mice were pretreated with an Ifnar1-specific blocking antibody and inoculated with 10 5 FFUs of mouse-adapted ZIKV-Dakar. The mice were then administered a single dose of EDE1-B10 or an isotype control mAb at day +1 (100 µg), day +3 (250 µg), or day +5 (250 µg) after infection, and viral RNA levels were assessed at day +5 (acute phase) or at day +21 (persistent phase) after infection. Treatment at day +1 decreased the levels of ZIKV RNA in serum at day +5 (52-fold; P < 0.001; Fig. 2g ). Similarly, EDE1-B10 therapy at day +1 reduced viral RNA levels in the following tissues at day +5 ( Fig. 2h-j ) and day +21 ( Fig. 2l-n) , relative to that observed in mice treated with the isotype control mAb: brain (1,760-fold and 42-fold, respectively; P < 0.001), testis (1,650-fold and 312-fold, respectively; P < 0.001), and epididymis (4,780-fold and 206-fold, respectively; P < 0.001). Whereas reduced levels were observed in the eye at day +5 after EDE1-B10 therapy at day +1 (1,550-fold; P < 0.001; Fig. 2k ), ZIKV RNA levels were low at day +21 in EDE1-B10 and isotype control mAb groups suggesting clearance occurred independently of mAb treatment (Fig. 2o) .
In another set of experiments, we treated mice with EDE1-B10 at day +3 after infection and evaluated viral burden in tissues at day +5 and day +21 after infection. Treatment with EDE1-B10 at day +3 after infection had less of an effect on viral RNA levels at day +5 than treatment with EDE1-B10 at day +1, with smaller reductions observed in serum (fourfold; P < 0.05), brain (ninefold; P < 0.001), testis (threefold; P > 0.05), epididymis (116-fold, P < 0.001), and eye (threefold; P < 0.05) ( Fig. 2g-k) . In comparison, EDE1-B10 treatment at day +3 after infection resulted in decreased ZIKV RNA levels in the testis (62fold; P < 0.05) and epididymis (1,800-fold; P < 0.05) at day +21 after infection, although levels in the brain were not affected, as compared to the treatment with the isotype control mAb ( Fig. 2l-n) .
Finally, we evaluated EDE1-B10 therapy at day +5 after infection for its effect on viral burden at day +21. However, treatment with EDE1-B10 beginning at day +5 after infection failed to decrease ZIKV RNA levels at day +21 in any of the sites tested, as compared to that after treatment with the isotype control mAb ( Fig. 2l-o) . To begin to define why EDE1-B10 was protective at some sites but not others, we measured mAb levels in tissues at day +5 after therapy was initiated at day +1 or day +3 after infection ( Supplementary Fig. 2) . Although the levels of EDE1-B10 in serum at day +5 were relatively equivalent, levels of the mAb in the brain and testis were lower (P < 0.01) when therapy was started at day +1 after infection than at day +3 after infection. This may reflect the dimished systemic viral burden associated with treatment at day +1 after infection, which we speculate limits pro-inflammatory immune responses that compromise the function of the blood-brain barrier and the blood-testis barrier and allows EDE1-B10 access. Notably, lower amounts of EDE1-B10 penetrated into the eye at day +5 after treatment regardless of when the treatment was initiated, which may be due to a less permeable blood-retinal barrier 33 . Because treatment at day +5 failed to reduce viral RNA levels at day +21, this suggested that once immune-privileged sites were seeded, it may be difficult to accumulate sufficient amounts of the EDE1-B10 mAb to control or clear the infection. In summary, these experiments show that there is a narrow window of time after infection during which treatment with the EDE1-B10 mAb is able to reduce ZIKV RNA levels in some, but not other, immune-privileged sites once viral seeding had occurred. To corroborate the protective effects observed with EDE1-B10 therapy, we evaluated ZIKV infection in the male reproductive tract at day +21 using RNA in situ hybridization (ISH). RNA ISH confirmed the absence of ZIKV RNA in the testis and epididymis of mice treated with EDE1-B10 at day +1 after infection and showed reduced viral RNA levels when treatment was initiated at day +3 after infection ( Fig. 3a and Supplementary Fig. 3 ). By comparison, mice treated with the isotype control mAb had high viral RNA levels, similar to those reported for untreated, infected mice 27 . Treatment with EDE1-B10 at day +1 or day +3 after infection also protected against ZIKV-induced inflammation and damage to the seminiferous tubules that was observed in mice treated with the isotype control mAb ( Fig. 3b and Supplementary Fig. 3 ) and described previously 27, 28 .
In contrast, treatment that was initiated at day +5 after infection minimally protected against ZIKV infection or injury. We also evaluated the functional effect of EDE1-B10 treatment in the testis by computer-assisted sperm analysis. Whereas ZIKV-infected mice treated with the isotype control mAb showed low numbers of motile sperm, treatment with EDE1-B10 at day +1 or day +3 after infection but not at day +5 after infection resulted in higher numbers of motile sperm (16-fold and 100-fold, respectively; P < 0.001) at day +21 after infection (Fig. 3c) , which were similar to those observed in age-matched, uninfected male mice (Fig. 3c) . These data suggest that EDE1-B10 treatment can reduce viral persistence in select immuneprivileged sites (for example, brain and testis) and protect against tissue injury when administered within a few days of infection.
EDE1-B10 therapy in maternal and fetal tissues
In pregnant mice that are deficient in type I interferon signaling, placental damage, and fetal infection and injury, occur after ZIKV infection 24, 29, 34, 35 . To assess the protective ability of EDE1-B10 treatment during pregnancy, we mated Ifnar1 −/− dams with WT C57BL/6 sires, and on embryonic day 6.5 (E6.5), we inoculated the dams subcutaneously with a Brazilian ZIKV strain (Paraiba 2015) 19, 34 . One day after infection (at E7.5), we administered a single 250-µg dose of EDE1-B10 or an isotype control mAb and monitored the effects on the A r t i c l e s Ifnar1 −/− dam and the Ifnar1 +/− placenta and fetus. Seven days after ZIKV inoculation (at E13.5), we observed a 90% rate of fetal demise in the group that was treated with the isotype control mAb versus a 10% rate of fetal demise in the group that was treated with EDE1-B10 (P < 0.0001) (Fig. 4a, left) . Histological analysis confirmed that the fetal demise caused by ZIKV infection was prevented by the EDE1-B10 therapy (Fig. 4a, right) . Consistent with these data, EDE1-B10 treatment at day +1 after infection reduced viral RNA burden in the maternal serum (~71-fold; P < 0.01) and brain (~39,000-fold; P < 0.05) at day +7 after infection, as compared to that after treatment with the isotype control mAb (Fig. 4b,c) . Analysis of the placentas by ISH showed ZIKV RNA in the maternal decidua and the junctional layer of the placenta in the mice that were treated with the isotype control mAb; in contrast, viral RNA staining was not observed in the dams that were treated with EDE1-B10 ( Fig. 4d) . Histological analysis after ZIKV infection showed reductions in the size of the labyrinth layer of the placenta in the control-mAb-treated dams, but this was not seen for the dams that were treated with EDE1-B10 at day +1 after infection (Fig. 4e) .
The extent of fetal demise after ZIKV infection of Ifnar1 −/− dams precluded virological assessment of EDE1-B10 protection in the fetus. To obtain such data, we used a second model of ZIKV infection in pregnancy with an acquired deficiency of type I interferon signaling 19, 34 . WT females that were mated with WT males were treated with an Ifnar1-specific blocking mAb at E5.5. One day later (at E6.5), the dams were inoculated subcutaneously with mouseadapted ZIKV-Dakar, and 1 d (at E7.5) or 3 d (at E9.5) later they were treated with EDE1-B10 or an isotype control mAb. Treatment of pregnant dams with EDE1-B10 at day +1 after infection resulted in reduced levels of viral RNA in the maternal serum (~240-fold; P < 0.001) and brain (~3,000-fold; P < 0.05), as compared to that in the serum and brain of dams that were treated with the isotype control mAb (Fig. 5a,b) . When treatment was initiated at day +1 after infection, we observed markedly less ZIKV RNA levels in the placenta and fetal head (660,000-fold and 4,900-fold, respectively; P < 0.0001) of EDE1-B10-treated dams than in those of the control-mAb-treated dams (Fig. 5c,d) . Treatment of dams with EDE1-B10 at day +3 after infection also reduced ZIKV RNA levels in the maternal serum (22fold; P < 0.05) and brain (114-fold; P < 0.001), as compared to that in the dams that were treated with the isotype control mAb (Fig. 5a,b) . Although ZIKV levels in the placenta (23-fold; P < 0.0001) and fetal head (19-fold; P < 0.0001) were lower in the EDE1-B10-treated group than in the control-mAb-treated group, therapy administered at this time point did not prevent virus seeding (Fig. 5c,d) .
We next evaluated whether antibody effector functions were required for EDE1-B10-mediated protection. We generated a mutant version of the EDE1-B10 mAb (LALA variant) 32 that was unable to bind to FcγR and promote ADE (Fig. 1c) , and we tested its efficacy in vivo during pregnancy. Like therapy with the recombinant WT EDE1-B10 mAb, treatment of dams with EDE1-B10 LALA at day +1 after infection resulted in reduced viral RNA levels in the maternal serum (240-fold; P < 0.01), maternal brain (3,000-fold; P < 0.05), placenta (633,000-fold; P < 0.0001), and fetal head (4,600-fold; P < 0.0001) ( Fig. 5a-d) . Analogous experiments with paired recombinant WT EDE1-C8 and EDE1-C8 LALA yielded similar results (Supplementary Fig. 4) . Thus, in utero protection mediated by EDE1 mAbs occurs independently of Fc effector functions and is probably mediated by direct virus neutralization. The mutant mAbs that are unable to bind FcγR could be safer immunotherapies, as they lack the potential to mediate ADE and immunopathogenesis.
To corroborate the protective effects the EDE-B10 mAb in the placenta, we analyzed tissue sections for virus infection and tissue injury. RNA ISH of placentas from dams that were treated at day +1 after infection showed a virtual absence of ZIKV-infected cells in the decidua and placenta, and mice that were treated at day +3 after infection also showed reduced viral RNA staining in these tissues, as compared to that in the tissues of control-mAb-treated dams (Fig. 5e) . Histological measurements of the placental layers showed that treatment at day +1 after infection, but not at day +3 after infection, with EDE1-B10 restored the area and width of the junctional area, the total placental area, and the overall fetal size (Fig. 5f-i) , as compared to treatment with the isotype control mAb. These data confirm a narrow therapeutic window for EDE1-B10 in preventing ZIKV infection and injury to the developing placenta and fetus.
Sexual transmission is an established route of ZIKV infection [36] [37] [38] [39] [40] [41] . Male-to-female transmission of ZIKV has been modeled in pregnant mice through direct intravaginal inoculation of virus 29 . Although recent vaccine studies indicate that adaptive immune responses can protect against in utero transmission for ZIKV inoculated subcutaneously 42 , no study has shown this in the context of vaginal transmission. We assessed whether administration of EDE1-B10 through a peripheral route could prevent in utero transmission following intravaginal inoculation of ZIKV (Fig. 6) . WT dams that were mated with WT sires were then treated with the Ifnar1-specific blocking mAb and A r t i c l e s a single 250-µg dose of EDE1-B10 or isotype control mAb at E5.5. At E6.5, the dams were inoculated with mouse-adapted ZIKV-Dakar via the intravaginal route. At E7.5, the dams were given a second dose of anti-Ifnar1. At E13.5, we determined the viral RNA burden in maternal and fetal tissues, including those of the female reproductive tract. Treatment with EDE1-B10 reduced ZIKV RNA levels in the maternal serum (427-fold; P < 0.05) and brain (45,490-fold; P < 0.01) ( Fig. 6a,b) , as compared to those in the control-mAb-treated mice.
In EDE1-B10-treated dams, ZIKV RNA levels were diminished, relative to those in the control-mAb-treated mice, in all female reproductive-tract tissues, including the vagina (106,840-fold; P < 0.01), cervix (12,450-fold; P < 0.01), and ovaries (341,300-fold; P < 0.01) ( Fig. 6c-e ). Because EDE1-B10 treatment also reduced ZIKV RNA levels in the placenta (1,725,600-fold; P < 0.0001) and fetal head (3,020-fold; P < 0.0001) ( Fig. 6f,g) , this indicated that circulating neutralizing antibodies can prevent transvaginal transmission of ZIKV to the placenta and fetus. Consistent with these data, staining by ISH showed a virtual absence of ZIKV RNA in the placenta and decidua of EDE1-B10-treated dams, as compared to that in control-mAb-treated dams (Fig. 6h) . Overall, these experiments establish that EDE1-B10 therapy can protect against ZIKV infection and transmission to the fetus after subcutaneous or intravaginal inoculation.
DISCUSSION
A primary goal of this study was to identify human mAbs that could potently neutralize ZIKV and provide post-exposure protection in vivo, including reduction of infection in key immune-privileged sites. Prior studies had shown that EDE-specific mAbs that had been isolated from DENV-infected subjects could neutralize DENV and ZIKV in vitro 10, 11 and protect against ZIKV lethality in vivo when administered as prophylaxis 22 . Studies with more ZIKV-specific human mAbs that do not cross-react with DENV also have demonstrated post-exposure therapeutic activity in lethality models in mice 17, [19] [20] [21] . On the basis of in vitro neutralization studies, we defined EDE1-B10 as a candidate immunotherapeutic because of its strong inhibitory activity against three virus strains that encompass the genetic diversity of ZIKV, as well as its neutralizing activity against DENV-1, DENV-2, and DENV-3. Of interest, EDE1-B10 failed to bind or neutralize DENV-4 efficiently; this phenotype was similar to that described for cross-reactive mouse mAbs to DENV that react with the DII-FL epitope 43 . We compared EDE1-B10 with the previously published EDE-specific mAbs 10,11 EDE1-C8 and EDE2-A11 for their post-exposure therapeutic activity against lethal ZIKV challenge. Although all three EDE-specific mAbs completely protected when given 3 d after ZIKV inoculation, EDE1-B10 also reduced lethality when administered 5 d after infection. The combination of increased neutralizing and protective activity led us to select EDE1-B10 for subsequent studies. We assessed how EDE1-B10 functioned at immune-privileged sites, which were seeded within 2 d of virus inoculation. ZIKV replication in immune sanctuary sites may contribute to its persistence in human and animal body fluids, including semen, urine, and saliva 27, 28, 44, 45 . During the acute phase of infection, EDE1-B10 treatment markedly reduced viral RNA in multiple immune-privileged sites when administered at day +1 after infection. However, the reductions were lower in magnitude when EDE1-B10 treatment was initiated at day +3 after infection. Correspondingly, persistence of ZIKV RNA at day 21 after inoculation was markedly diminished at most immune-privileged sites when therapy was initiated at day +1 after infection. However, when therapy was started at day +3 after infection, viral RNA persisted at day +21 after infection at several immune-privileged sites (eye, brain, and testis). Thus, the likely protective role of the EDE1 mAbs is to limit ZIKV dissemination, with antibody-mediated clearance of already infected sites being substantially less efficient. Consistent with this observation, protection of the placenta and fetuses by the WT and LALA variants of EDE1-B10 and EDE1-C8 was equivalent in the dam model of infection and was not dependent on Fcdependent interactions. These results contrast with those in HIV 32 , Ebola virus 46 , influenza A virus 47 , and respiratory syncytial virus 48 studies in which antibody effector functions enhanced protection. Fc effector functions may contribute to antibody-mediated protection of these viruses because, unlike ZIKV, they bud from the plasma membrane and express structural proteins on the cell surface, which can serve as targets for antibody-dependent cellular cytotoxicity and phagocytosis.
Sexual transmission is an established route of ZIKV spread and of concern to individuals within and traveling to endemic regions, particularly for those of child-bearing age. Our study shows that systemic mAb administration can protect against intravaginal transmission of ZIKV infection in the context of pregnancy. This observation is relevant, as studies in macaques suggest that ZIKV replication in the female reproductive tract precedes infection of peripheral organ tissues that contribute to viremia 49 . Our passive antibodytransfer experiments in mice suggest that ZIKV vaccines that induce robust neutralizing antibody responses and protect against in utero transmission after subcutaneous virus challenge 42 may also prevent sexual transmission.
ZIKV epidemics in the Americas now occur in DENV-endemic regions. Cross-reactive antibodies against ZIKV and DENV could protect or mediate pathogenesis 50 depending on the stoichiometry of binding and mechanism of action 31 . Our preclinical studies with LALA variants of EDE1-B10 and EDE1-C8 provide a first step toward developing a safe and effective therapeutic antibody against both ZIKV and DENV, without the possibility for pathogenic immune enhancement. Nonetheless, as the extent to which these findings in mice translate to humans remains unclear, protection studies with EDE1 mAbs in nonhuman primate models of ZIKV infection in pregnancy are warranted. If these data are promising, then human clinical trials will be required to show efficacy. The design of such trials will be challenging given the ephemeral nature of mosquito-transmitted virus epidemics in a given locale and the absolute need for safety in the context of transmission studies with pregnant women.
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